ENLON-PLUS
LOE Approachingatropine sulfate; edrophonium chloride
NDAINJECTIONINJECTABLE
Approved
Nov 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ENLON-PLUS (atropine sulfate; edrophonium chloride) is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1991.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENLON-PLUS is a fixed-dose combination injectable containing atropine sulfate (an antimuscarinic agent) and edrophonium chloride (a cholinesterase inhibitor), approved in 1991. It blocks muscarinic receptor activation to produce mydriasis and cycloplegia, making it indicated for ophthalmologic procedures including cycloplegia, mydriasis, and amblyopia treatment in adults. The dual mechanism allows atropine's anticholinergic effects to be paired with edrophonium's acetylcholine-potentiating activity for diagnostic and therapeutic ophthalmic applications.
LOE Approaching
With LOE approaching and minimal current spending data, the brand team is likely consolidating resources and preparing transition strategies for post-exclusivity competition.
Mechanism of Action
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.